• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

勘误：用于心律失常风险评估的心脏细胞模型的优化。

Corrigendum: Optimization of an Cardiac Cell Model for Proarrhythmia Risk Assessment.

作者信息

Dutta Sara, Chang Kelly C, Beattie Kylie A, Sheng Jiansong, Tran Phu N, Wu Wendy W, Wu Min, Strauss David G, Colatsky Thomas, Li Zhihua

机构信息

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States.

Marshview Life Science Advisors, Seabrook Island, SC, United States.

出版信息

Front Physiol. 2017 Dec 6;8:1025. doi: 10.3389/fphys.2017.01025. eCollection 2017.

DOI:10.3389/fphys.2017.01025
PMID:29230183
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5723676/
Abstract

[This corrects the article on p. 616 in vol. 8, PMID: 28878692.].

摘要

[这更正了第8卷第616页上的文章， PMID: 28878692。]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654c/5723676/ec233e049de6/fphys-08-01025-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654c/5723676/ec233e049de6/fphys-08-01025-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654c/5723676/ec233e049de6/fphys-08-01025-g0001.jpg

相似文献

1
Corrigendum: Optimization of an Cardiac Cell Model for Proarrhythmia Risk Assessment.勘误：用于心律失常风险评估的心脏细胞模型的优化。
Front Physiol. 2017 Dec 6;8:1025. doi: 10.3389/fphys.2017.01025. eCollection 2017.
2
Optimization of an Cardiac Cell Model for Proarrhythmia Risk Assessment.用于心律失常风险评估的心脏细胞模型的优化
Front Physiol. 2017 Aug 23;8:616. doi: 10.3389/fphys.2017.00616. eCollection 2017.
3
Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for Proarrhythmia Risk Assessment.不确定性量化揭示了数据变异性和实验设计考量在致心律失常风险评估中的重要性。
Front Physiol. 2017 Nov 21;8:917. doi: 10.3389/fphys.2017.00917. eCollection 2017.
4
Introduction to model for proarrhythmic risk assessment under the CiPA initiative.CiPA倡议下的致心律失常风险评估模型介绍。
Transl Clin Pharmacol. 2019 Mar;27(1):12-18. doi: 10.12793/tcp.2019.27.1.12. Epub 2019 Mar 27.
5
The influence of hERG1a and hERG1b isoforms on drug safety screening in iPSC-CMs.hERG1a 和 hERG1b 异构体对 iPSC-CMs 药物安全筛选的影响。
Prog Biophys Mol Biol. 2019 Dec;149:86-98. doi: 10.1016/j.pbiomolbio.2019.02.003. Epub 2019 Feb 27.
6
Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.安全药理学中的心脏电压门控离子通道：促成CiPA计划的研究概况综述
J Pharmacol Toxicol Methods. 2017 Sep;87:11-23. doi: 10.1016/j.vascn.2017.04.002. Epub 2017 Apr 11.
7
An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.针对综合体外致心律失常试验（CiPA）提出的离子通道组，对30种临床药物进行评估。
J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:251-62. doi: 10.1016/j.vascn.2016.03.009. Epub 2016 Apr 6.
8
Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence.
Circulation. 1996 Feb 1;93(3):407-11. doi: 10.1161/01.cir.93.3.407.
9
Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs.新药致心律失常风险评估的不断演变的监管范式
J Electrocardiol. 2016 Nov-Dec;49(6):837-842. doi: 10.1016/j.jelectrocard.2016.07.017. Epub 2016 Jul 28.
10
Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice.致心律失常倾向评估与体外综合致心律失常试验（CiPA）：当前实践的行业调查
J Pharmacol Toxicol Methods. 2017 Jul;86:34-43. doi: 10.1016/j.vascn.2017.02.021. Epub 2017 Feb 20.

引用本文的文献

1
Validation of new AI-based classification method for in silico cardiac safety assessment of drugs following the CiPA framework.遵循CiPA框架对基于人工智能的药物计算机心脏安全性评估新分类方法的验证。
Arch Toxicol. 2025 May 22. doi: 10.1007/s00204-025-04079-z.
2
Basic Research Approaches to Evaluate Cardiac Arrhythmia in Heart Failure and Beyond.评估心力衰竭及其他情况下心律失常的基础研究方法
Front Physiol. 2022 Feb 7;13:806366. doi: 10.3389/fphys.2022.806366. eCollection 2022.
3
Heart Muscle Microphysiological System for Cardiac Liability Prediction of Repurposed COVID-19 Therapeutics.
用于预测新冠病毒病（COVID-19）治疗药物心脏安全性的心肌微生理系统
Front Pharmacol. 2021 Aug 4;12:684252. doi: 10.3389/fphar.2021.684252. eCollection 2021.